Fig. 3: Actifensin’s effects on human cells.
From: Trans-kingdom conservation of mechanism between bacterial actifensin and eukaryotic defensins
a Relative viability of human epithelial cells (Hep G2) following 24 h of actifensin treatment, calculated as a percentage of untreated cells. b Relative viability of human erythrocytes following actifensin treatment for 24 h. Actifensin does not modulate TNF release in PBMCs stimulated with c LPS, d Pam3CSK4, or e heat-inactivated S. aureus (6.5 × 108 cfu/ml in stationary phase or 6.9 × 108 cfu/ml in mid-logarithmic phase). Bar graphs show mean + SEM (n = 3–5). n.d. not detected.
